JAK2 and acquired polycythemia vera: In PV patients, although the role of JAK2 V617F mutation in progression toward fibrosis is currently unknown, transition from heterozygoty to homozygoty for JAK2 may represent an important step in the progression toward post-PV myelofibrosis [49].